<DOC>
	<DOCNO>NCT01306214</DOCNO>
	<brief_summary>This trial evaluate use BI 10773 add-on insulin regimen alone metformin patient typr 2 diabetes . Both lower glucose HbA1c reducing use insulin population would provide significant new information BI 10773 use would offer potential new therapeutic option population .</brief_summary>
	<brief_title>Safety Efficacy BI 10773 add-on Insulin Regimen Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis T2DM prior inform consent 2 . Male female patient diet exercise regimen pretreated multiple daily injection ( MDI ) insulin alone combination immediate extend release metformin 3 . Stable metformin therapy : daily dose &gt; =1500 mg/day maximum tolerate dose 4 . HbA1c &gt; =7.5 % &lt; =10 % screen Exclusion criterion : 1 . Uncontrolled hyperglycemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast placebo runin 2 . Any contraindication metformin accord local label 3 . Acute coronary syndrome , stroke TIA within 3 month prior inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>